Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,689 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 537 of 641 · 7,689 filings

  • Ginkgo Bioworks Holdings (DNA) FY2024 10-K risk factors
    64 risks

    Ginkgo faces continuing operating losses, an accumulated deficit of $5.8 billion, and reliance on a concentrated group of customers.

    Filed Feb 25, 2025
  • DigitalOcean Holdings (DOCN) FY2024 10-K risk factors
    60 risks

    DigitalOcean faces risks from scaling AI/ML products, managing recent executive leadership changes, and maintaining cloud infrastructure capacity.

    Filed Feb 25, 2025
  • Euronet Worldwide (EEFT) FY2024 10-K risk factors
    36 risks

    Euronet Worldwide relies heavily on international operations, third-party bank partners, and foreign exchange markets for its payment, ATM, and money transfer segments.

    Filed Feb 25, 2025
  • Elanco Animal Health (ELAN) FY2024 10-K risk factors
    48 risks

    Elanco faces intense competition, high indebtedness of $4.3 billion, and substantial regulatory oversight across global markets. R&D failures, manufacturing disruptions, and shifting consumer trends toward alternatives could significantly impact product demand.

    Filed Feb 25, 2025
  • Equity Lifestyle Properties (ELS) FY2024 10-K risk factors
    52 risks

    Equity Lifestyle Properties faces significant geographic concentration risk in Florida and California, exposing its real estate portfolio to natural disasters and climate changes. Substantial leverage, floating debt exposure, and ongoing capital expenditure needs heavily influence operational cash flows and REIT dividend obligations. Regulatory burdens like rent control laws and licensing rules for chattel financing threaten manufactured home and RV community operations.

    Filed Feb 25, 2025
  • EverQuote (EVER) FY2024 10-K risk factors
    30 risks

    EverQuote faces significant customer concentration with its largest insurance carrier generating 39% of 2024 revenue. The business is heavily exposed to strict regulations on data privacy, telemarketing, email, and insurance marketing. Technology risks center on cookie restrictions, cybersecurity, and artificial intelligence integration.

    Filed Feb 25, 2025
  • ExlService Holdings (EXLS) FY2024 10-K risk factors
    34 risks

    ExlService Holdings faces significant risks tied to rapid AI adoption, client concentration in the US, and offshore wage costs.

    Filed Feb 25, 2025
  • Fortune Brands Innovations (FBIN) FY2024 10-K risk factors
    22 risks

    The risk section is dominated by the recent tax-free spin-off and separation of MasterBrand into an independent publicly traded company. Supply chain dependencies, global sourcing risks, raw material cost volatility, and customer concentration significantly impact operations. Intellectual property protection, technological changes, and labor constraints represent major operational hurdles.

    Filed Feb 25, 2025
  • FB Financial (FBK) FY2024 10-K risk factors
    38 risks

    Loan portfolios heavily concentrated in real estate and commercial lending dominate risk exposure. Mortgage banking operations and interest rate fluctuations significantly impact revenue and asset values. Regulatory compliance, technology changes, and competitive pressures across Tennessee markets shape ongoing operational risks.

    Filed Feb 25, 2025
  • Fortive (FTV) FY2024 10-K risk factors
    35 risks

    Fortive's risk profile is dominated by pending structural separation transactions, extensive global regulatory exposure, and ongoing M&A and integration strategies.

    Filed Feb 25, 2025
  • Fulcrum Therapeutics (FULC) FY2024 10-K risk factors
    83 risks

    Fulcrum Therapeutics faces significant ongoing operating losses, with an accumulated deficit of $519.4 million as of December 31, 2024. The company suspended development of losmapimod after its Phase 3 REACH trial failed its primary endpoint. Current development relies heavily on pociredir and maintaining sufficient cash to fund operations into 2027.

    Filed Feb 25, 2025
  • Glacier Bancorp (GBCI) FY2024 10-K risk factors
    27 risks

    Glacier Bancorp faces concentrated economic exposure across eight Western states, significant credit risk from real estate loans, and growth dependence on bank acquisitions.

    Filed Feb 25, 2025

Companies covered

4,011 companies

371 more under A